We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
- Authors
Bakiner, Okan; Ertorer, Melek E.; Bozkirli, Emre; Tutuncu, Neslihan B.; Demirag, Nilgun G.
- Abstract
Aim of this prospective study is to evaluate the effect of repaglinide t.i.d. (three times a day) plus single-dose insulin glargine regimen in low-risk type 2 diabetic patients during Ramadan fasting. Participants had been taking the regimen for at least 3 months. Patients with a history of diabetic coma, severe hypoglycemic crisis or repeating attacks of hypoglycemia were excluded. Hypoglycemic unawareness, kidney or liver disease or HbA1c over 8% were also accepted as exclusion criteria. Eleven patients who insisted on this worship and eight non-fasting cases were involved. All were told to make home-glucose-monitorisation weekly and report any hypoglycemic event throughout Ramadan. Fasting blood glucose (FBG), post-prandial blood glucose (PBG) and fructosamine levels, body weights and blood pressures were recorded just before and after Ramadan. Seven patients in each group concluded the follow-up. Any significant change was detected in the parameters in either groups ( P > 0.05). Glucose control remained unchanged; fructosamine 318.14 ± 65.38 versus 317.28 ± 52.80 mmol/L in fasting group, 290.71 ± 38.48 versus 290 ± 38.56 mmol/L in non-fasting group. None of them exhibited either a major or a minor hypoglycemic event. The results of this pilot study indicated that repaglinide t.i.d. plus single-dose insulin glargine regimen was safe for low-risk type 2 diabetic patients who insisted on fasting during Ramadan.
- Subjects
INSULIN; PEOPLE with diabetes; HYPOGLYCEMIC sulfonylureas; HYPOGLYCEMIA; ENDOCRINE diseases
- Publication
Acta Diabetologica, 2009, Vol 46, Issue 1, p63
- ISSN
0940-5429
- Publication type
Article
- DOI
10.1007/s00592-008-0062-7